Moguisteine

Moguisteine

Identifiers
IUPAC name Ethyl 3-{2-[(2-methoxyphenoxy)methyl]-1,3-thiazolidin-3-yl}-3-oxopropanoate
CAS Number	119637-67-1 Y
PubChem CID	65935
ChemSpider	59340
UNII	6Y556547YY
ChEMBL	ChEMBL146980
Chemical and physical data
Formula	C16H21NO5S
Molar mass	339.41 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)CC(=O)N1CCSC1COC2=CC=CC=C2OC
InChI InChI=1S/C16H21NO5S/c1-3-21-16(19)10-14(18)17-8-9-23-15(17)11-22-13-7-5-4-6-12(13)20-2/h4-7,15H,3,8-11H2,1-2H3 Key:WSYVIAQNTFPTBI-UHFFFAOYSA-N

Moguisteine is a non-narcotic, peripherally acting antitussive. In a small double-blind, randomized controlled trial, 200 mg of moguisteine suspension taken 3 times daily significantly reduced the frequency of coughing in patients with COPD, compared to placebo. It has also been studied in small trials in comparison to codeine and dextromethorphan, and has similar efficacy to both. It has not been approved for use in the United States.

It was discovered by searching for expectorants of the thiazolidine class, when compounds with a cough suppressant effect were accidentally found and moguisteine was selected as the most effective and safest representative of the class. Its mechanism of action may be the activation of ATP-sensitive potassium channels.